ReviewTargeted oncology2015
Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
Review in Targeted oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation.Discover oncology · 2025Article
- Systemic treatment for metastatic colorectal cancer.World journal of gastroenterology · 2023Review
- The implication of BRAF mutation in advanced colorectal cancer.Irish journal of medical science · 2022Article
- Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?Annals of gastroenterological surgery · 2021Review
- Colorectal liver metastases: Current management and future perspectives.World journal of clinical oncology · 2020Review
- Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine.Journal of clinical medicine · 2020Review
- The heterogeneous clinical and pathological landscapes of metastaticCancer cell international · 2020Review
- Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.European biophysics journal : EBJ · 2019Article
- Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2018Review
- Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage.Molecular cancer therapeutics · 2018Article
- How theGastroenterology research and practice · 2018Review
- Understanding and Resetting Radiation Sensitivity in Rectal Cancer.Annals of surgery · 2017Article
- Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.Surgical oncology · 2016Review
- Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.World journal of gastroenterology · 2016Review
- The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment ofFrontiers in pharmacology · 2016Article
- The chromosome 3q26 OncCassette: A multigenic driver of human cancer.Advances in biological regulation · 2016Article
- VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing knowledge of the underlying signaling pathways and molecular defects involved in colorectal cancer growth or progression enabled the discovery of several prognostic and predictive biomarkers, leading to the development of novel molecularly targeted therapies. The mitogen-activated protein kinase (MAPK) signaling pathway plays a critical role in colorectal cancer progression. Mutations in BRAF, a principal effector of Ras in this signaling cascade, are found in 10 % of colorectal cancer and play a clear pathogenic role, particularly in patients with metastatic disease. Intense efforts have therefore focused on targeting BRAF as an oncogenic driver, with mixed early results. This article summarizes the molecular and clinical features of BRAF mutant colorectal cancer, the prognostic and predictive role of BRAFV600E mutation in colorectal cancer, initial clinical trial results in targeting BRAFV600E, and the more recent preclinical insights into potential mechanisms of resistance to BRAF inhibition that have now led to a number of rationale-driven combination therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.